

31. (amended) A method according to claim 26 wherein said cells are mammalian cells.

32. (amended) A method according to claim 26 wherein said library comprises at least 10^4 different nucleic acids.

33. (amended) A method according to claim 26 wherein said library comprises at least 10^5 different nucleic acids.

34. (amended) A method according to claim 26 wherein said library comprises at least 10^6 different nucleic acids.

35. (amended) A method according to claim 26 wherein said library comprises at least 10^7 different nucleic acids.

36. (amended) A method according to claim 26 wherein said library comprises at least 10^8 different nucleic acids.

37. (amended) A method according to claim 26 wherein each of said candidate nucleic acids is linked to nucleic acid encoding at least one fusion partner.

REMARKS

Claims 26-45 are the currently pending claims. Claims 23-25 and 46-50 have been canceled as drawn to a non-elected group, without prejudice to refiling on the claimed subject matter. Claims 28-37 have been amended to recite dependency only on the elected claim group. No new matter is added.

Applicants elect the invention of Group II, claims 26-45, and elect the species of fusion partner a, presentation sequence.

CONCLUSION

Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.